Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights:NZs regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publicati...
Source: businessinsider.com
📰 Colorectal Dysfunction News
Colorectal Dysfunction News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Colorectal Dysfunction. Real-time updates on events, politics, business and more.
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
/PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease...
Source: prnewswire.com
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights: MELBOURNE, Australia, Jan. 27, 2022 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31st December 2021 (Q2 FY22). The Company's cash position on...
Source: asiaone.com
Appendix 4C - Q2 FY22 Quarterly Cash Flow Report
Highlights: NZ’s regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdictions to follow New poster presentation and publications...
Source: fnarena.com
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
United States San Francisco David Stamler National Institute Of Health Parkinson Foundation European Commission
Source: prnewswire.com
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
Colorectal impairment reversed in a preclinical model of Parkinson’s Disease ATH434 presents a novel mechanism of action for the treatment...
United States San Francisco David Stamler National Institute Of Health Parkinson Foundation European Commission
Source: fnarena.com